Journey Biosciences—a biotechnology company with a proactive diagnostic screening technology for high-risk kidney complications associated with diabetes, has announced its company launch, and the introduction of its flagship product, NaviDKD.
NaviDKD is a diagnostic screening technology that analyses blood-based predictive biomarkers to determine an individual’s risk factor for developing high-risk kidney complications, including diabetic kidney disease (DKD).
Combined with Journey Biosciences’ proprietary Compass reporting platform, NaviDKD not only proactively identifies an individual’s risk factor, but also provides actionable insights to prevent and manage complications before they occur, according to a company press release.
“Currently, more than 34 million Americans have diabetes—and one out of three will develop kidney disease,” said Adam Graybill, CEO of Journey Biosciences. “Most will develop complications without outward signs or symptoms. That is where Journey Biosciences and NaviDKD screening can make a difference in how we treat diabetes, changing the conversation from reactive to proactive. NaviDKD helps proactively identify those risks so people with diabetes and their healthcare team can take action now.”
